G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial

Blood Cancer J. 2022 Jul 7;12(7):105. doi: 10.1038/s41408-022-00698-2.

Abstract

GA trial is registered under EudraCT#: 2013-001639-38.

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use
  • Azacitidine* / therapeutic use
  • Granulocyte Colony-Stimulating Factor
  • Humans
  • Myelodysplastic Syndromes* / drug therapy

Substances

  • Antimetabolites, Antineoplastic
  • Granulocyte Colony-Stimulating Factor
  • Azacitidine